Tweet of the Day
Position: None
Position: None
Position: None
The S&P Short Range Oscillator remains overbought at 2.24% vs. 2.65%.
Position: None
After years of underperformance, biotech is finally catching a nice bid. Here’s my strategy on a name showing promise.
These names fell hard post earnings and look to have more downside action in store.
A high dividend yield can look like a ticket to lasting retirement income, until the cut arrives. Before rushing into a high-yield name, ask yourself three questions.
Here’s how to take advantage of down times in the market, to expect cycles of bullish and bearish periods, and become a better trader.
Let’s scan through the headlines for the stories of the week that speak to our Pro Portfolio holdings.
We locked in massive gains on two positions and added to two beaten-down holdings.
Good news from Trulieve ($TRLV) after the close.
Trulieve Announces Planned Termination of Executive Automatic Securities Disposition Plan
Position: Long TRLV (S)